

# Evaluation under REACH

Visit of Ministry of Environment  
and of Institute of Environment and  
Renewable Natural Resources of Brazil

15 April 2013

Marco Valentini & Dalia Garaleviciene  
Directorate E

# Outline

- Introduction
- Dossier evaluation
  - Compliance check
  - Testing proposal examination
- Substance evaluation
- Conclusions



## Evaluation: management system

- Directorate of Evaluation
  - Director: Leena Ylä-Mononen
- 3 Evaluation Units
  - Heads of Units: Wim De Coen (E1), Claudio Carlon (E2), Watze de Wolf (E3)
- 15 Dossier Evaluation Groups (DEGs)
- Co-operation with Directorates A (Communications), B (Legal Affairs and MSC-Secretariat), C (Substance Identity, QSAR), D (Exposure Assessment & Risk Management)



- **Pre-registration**
- **Data sharing**
- **Registration**

**Industry provides information**

**MSs**

- **Evaluation**
  - **Dossier evaluation**
  - **Substance evaluation**

**ECHA and MS-CAs control  
and request for further info**



- **Classification & labelling**
  - **Authorisation**
  - **Restriction**
- COM,  
with support of ECHA and MS-CAs,  
applies community wide  
risk management instruments**

**Provide confidence that industry is meeting obligations**  
**Prevent unnecessary animal testing**  
**Build up information basis for eventual risk management measures at EU level**

Dossier evaluation

Substance evaluation

Check test proposals

Compliance check

Examine any information on a substance

Output, e.g.:

- accept/reject a testing proposal
- request information, because the dossier is not compliant
- request information to clarify potential risks

## What is evaluation ? (2)

### Dossier evaluation

- ECHA evaluates:
  - testing proposals, *all of them!* (Art. 40)
  - compliance of dossiers, *at minimum 5% per tonnage band* (Art. 41)

### Substance evaluation


- MSCAs evaluate:
  - *selected substances*
- Community Rolling action plan (CoRAP)-list (ECHA) (Art. 44)
- Selection criteria (Art. 44): risk-based priority setting:
  - Hazard
  - Exposure
  - Aggregated tonnage

# **Dossier Evaluation:**

## ***Compliance check***



# Aims of the Compliance Check



- To check whether the information requirements are fulfilled in the registration dossiers
- To promote the quality of registrations
- **!** Main instrument to request missing information, if information requirements are not addressed (=non-compliance)



## When will the Agency perform a Compliance Check?


- The Agency may perform a compliance check of any registration dossier
- Some priority setting is suggested in the legislation:
  - Dossiers where information is submitted separately (opting-out of joint submission)
  - Dossiers [1, 10t], not fully falling under Annex VII (not fulfilling the criteria of Annex III)
  - Substance is on Community Rolling Action Plan (Substance Evaluation)
- Random selection
- Concern-driven selection

## What is checked for compliance?

That:

1. **Information in the technical dossier(s)** complies with the requirements of Art. 10, 12 and 13 and with Annexes III, VI to X;
2. **Adaptations** of the standard information requirements in the technical dossier(s) **comply** with Annexes VII to XI;
3. **Chemical Safety Assessment (CSA) and Chemical safety Report (CSR)** comply with Annex I and that the proposed **Risk Management Measures (RMM)** are adequate;
4. **Explanations** for separate submission from other registrants have an objective basis


# DEGs & support



## Possible outcomes of Compliance Check

- Conclusion document: **no communication**, internal document
- Communication to the registrant
  - **Draft decision**: request to provide information to make the dossier compliant + deadline for submitting further data
    - Legally binding
    - Communicated to the Member States
  - **Quality Observation letter**: observations, invitation to the registrant to improve the quality of the dossier
    - Not legally binding, but a follow-up process is in place
    - Communicated to MS

## Evaluation – the mechanics



## Follow-up of ECHA Decision

Registrant submits an updated dossier prior to the deadline set:

**a) Examination by ECHA**

- The update of the dossier is in line with the requests for further information
- The update of the dossier is found to be not in line with the request or the results are not taken into account in risk assessment: follow up action has to be decided
- Informing Commission and MSCAs of the conclusions

**b) Possible further EU-wide follow up**

- MSCAs/ECHA: Inclusion in Community Rolling Action Plan for Substance Evaluation
- MSCA: Annex XV dossier for authorisation
- MSCA: Annex XV dossier for restriction
- MSCA: C&L proposal

If no submission by the Registrant → MS enforcement matter

## **Dossier Evaluation:**

***Testing proposal  
examination***



## Aims of testing proposal examination (TPE)

- To stimulate and support industry towards efficient testing
- To conduct testing only if needed, in particular vertebrate animal testing





## When a testing proposal?

Required by REACH Annexes IX and X:

- Registrants identify a data gap and cannot otherwise fulfil the REACH information requirements;
- Additional testing is triggered by risk, e.g.:
  - available information of the substance is inconclusive;
  - further investigation is needed

## ECHA's tasks

Art. 40: the Agency shall evaluate any testing proposal in a registration or DU report

### Deadlines:

- for non phase-in substances: 180 days after receipt
- for phase-in substances:
  - by 1 Dec 2012 (if received by 1 Dec 2010; >1000 tpa, CMR...)
  - by 1 Jun 2016 (if received by 1 Jun 2013; 100-1000 tpa)
  - by 1 Jun 2022 (if received by 1 Jun 2018; 1-100 tpa)

## How to evaluate testing proposals?

Is the testing proposal justified?

- Is the test requested by Annexes IX-X?
- Is all available information considered?
- What impact on risk characterization, C&L or PBT/vPvB?
- Information received from the 3<sup>rd</sup> parties during public consultation should be considered

Is the testing proposal adequate?

- Is the proposed test method reliable and relevant?
- Is there a need to modify/adapt the test protocol?
- Is further testing needed?

- Expects to handle about 600 dossiers/year.
- 1 December 2012 deadline for TPs submitted by the first registration deadline of 30 November 2010; 571 dossiers with 1184 individual TPs. 436 draft decisions were issued.
- 2013 priority, to conclude the up to 1000 compliance checks necessary to achieve the 5% target.
- 2014 target is to achieve good progress in the evaluation of testing proposals submitted by the 2013 deadline.

# Substance Evaluation



# Substance evaluation

## Aim

- Clarification of a concern for human health or environment by requiring registrants to provide additional information

## Who performs the evaluation?

- Member States' competent authorities (MS-CAs)

## Decisions

- Requests for further information

## What substances?

- Community Rolling Action Plan (CoRAP)

|                            | <b>Substance evaluation<br/>(SEv)</b>   | <b>Compliance check<br/>(CCH)</b>                               |
|----------------------------|---|---|
| <b>Objective<br/>(Why)</b> | To verify the suspected risks   | To ensure compliance with the standard information requirements |
| <b>How</b>                 | Request for information needed to clarify the risks                                     | Request for information to fulfil standard requirements         |
| <b>What</b>                | Substances (all registration dossiers) included in CoRAP                                | Registration dossiers   |
| <b>Who</b>                 | Member State Competent Authorities  | ECHA  |
|                            | <b>Interlinked and complementary<br/>(a CCH can be performed in preparation of SEv)</b> |   |

## Role of MSCAs, Registrants and ECHA

---

- The Competent Authorities of the Member States (MSCA) evaluate the substances
- Registrants may be requested to update dossiers with further information
- ECHA coordinates the selection of substances to be evaluated (Community Rolling Action Plan) and the substance evaluation process in order to ensure a harmonised approach.

N.B. Any request of information will be proposed by the evaluating MSCA, but eventually made by ECHA



# Community Rolling Action Plan (CoRAP)

---



## Duration

- Covers three years

## What is it?

- List of substances to evaluate in each of the next three years, evaluating Member States and initial concerns
- Substance specific justification documents published (from 2013)

## Consequences of inclusion into CoRAP

- No legal impact for the Registrant
- Substances listed in the first year need to be evaluated within 12 months from the publication of the CoRAP
- Evaluation of substances listed for the 2<sup>nd</sup> and the 3<sup>rd</sup> year only starts from the publication of CoRAP updates in that year. They may be revised.

## CoRAP – selection criteria

---

Selection criteria based on risk [Art. 44(1) REACH]

General criteria refined in collaboration with MSCAs and published on ECHA website.

Combination of hazard and exposure criteria:

- e.g. suspected PBTs/vPvBs, endocrine disruptors, CMRs, sensitizers
- e.g. wide dispersive use, consumer use, aggregated tonnage

According to Art. 45(5) MSs can notify substances based on any risk concern

## **CoRAP development and adoption in collaboration with MSCAs**

---

### **Annual stepwise process:**

- Selection of CoRAP candidate substances (IT based selection + expert verification),
- Consideration of regulatory effectiveness of CoRAP inclusion,
- Tentative distribution among evaluating MSCAs,
- Draft CoRAP publication, submission to MS Committee for opinion (October)
- Adoption and publication of CoRAP (update; March)

## CoRAP publication

---

| CoRAP 2012-2014   | CoRAP 2013-2015  |
|---|--|
| Published 29 Feb 2012   | Published 20 March 2013  |
| Contains 90 substances: <ul style="list-style-type: none"><li>• 36 for 2012;</li><li>• 23 for 2013;</li><li>• 31 for 2014</li></ul> | Contains 115 substances: <ul style="list-style-type: none"><li>• 46 for 2013;</li><li>• 46 for 2014;</li><li>• 23 for 2015</li></ul> |
| 17 Member States evaluated substances   | 21 Member State will evaluated substances  |


## Complementary part to the CoRAP

---

- On 5 Sept 2012 ECHA published the list of pending evaluations originating from the previous legislation (NONS and ESR) that are regarded as included in the CoRAP.
- No new substances will enter to the complementary part of the CoRAP, the work will be just completed
- <http://echa.europa.eu/web/guest/information-on-chemicals/evaluation/community-rolling-action-plan/transitional-measures>

## Substance Evaluation process

---




## Substance Evaluation process

---


- Evaluation: from publication of CoRAP, evaluating MSCA has **12 months** for considering the need for further information and preparing request (draft decision).
- After adoption of decision, registrant(s) shall within timelines specified in the decision submit requested information to ECHA by updating the registration dossier(s) with new data.
- Follow up evaluation: Following this, MSCA must examine any information received and, if needed, draft any further appropriate decision within another 12 months of the information being submitted (Article 46(3)).

## Evaluation and outcomes (12 months)





## Follow up to Substance evaluation



The MSCA informs ECHA of its conclusions as to whether or how to use the information obtained (**Art. 48 – Follow-up**). ECHA informs the Commission, the Registrant and the other MSCAs.

## Interaction with Registrant(s)

---

**Formally** – opportunity to comment on a draft decision  
Value of a co-ordinated response from registrants

**Informally** – Registrant(s) can contact the MSs (details on the CoRAP)  
– MS can contact registrant(s) (issues with submission of updates/pending studies)

**Communication to the registrants and DU on how to act during SEv process**

–A leaflet “Tips for Registrants and DUs”  
under preparation

**Work on-going on a harmonised policy across MS**



## Interaction between MS

---

**Joint evaluations** – collaboration between MS

**Commenting** – formally only on a draft decision  
- no peer review of Sev reports

**Information sharing** – particularly when registrants are  
in another MS

**Harmonised approach** – workshops, commenting on  
documents

## Interaction with ECHA

---

- **ECHA has a co-ordination role**
  - Ensuring a harmonised approach
  - Organising guidance, workshops, consistency screening of draft decisions, etc
  - Publication of outcome documents
- Specific **contact person in ECHA** allocated for each substance
- Preparation of the CoRAP
- Updating prioritisation criteria

## Substance evaluation in 2012

---

- 36 substances evaluated
- Draft decisions prepared for 32 substances
- Evaluation of 4 substances concluded without sending a draft decision
  - Conclusion documents under preparation by MSs
- Substance evaluation in 2013:
  - Ongoing for 46 substances

## Substance Evaluation

- Substance Evaluation (SEv) complements the scope of Compliance Check (CCH): CCH may be performed in preparation of SEv
- SEv allows requesting further information on chemicals to clarify risk concerns. The information obtained should be considered by both industry and authorities for (regulatory) risk management

## Community Rolling Action Plan (CoRAP)

- Inclusion in the Community Rolling Action Plan (CoRAP) is just the first step to perform an evaluation and NOT a preliminary judgment on the actual risk
- The initial concern will not limit the scope of the evaluation (other concerns can be found and addressed)
- If a substance is included in the CoRAP, industry should coordinate with other registrants of the same substance and prepare to handle requests for comments and final requests for information

# Conclusions



## Conclusions

- The safe use of substances starts under REACH with high quality registration dossiers (industry's responsibility)
- Through the process of Evaluation, ECHA and Member States are empowered to request additional information when essential data are missing, risk concerns need to be clarified
- ECHA also provides recommendations for registrants to improve the quality of dossiers
- Evaluation is the key process in achieving the ultimate aims of REACH – **a safer future for us all!**



**Thank You.**

Marco Valentini  
Dalia Garaleviciene